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Abstract
Novel pathways in polycystic ovary syndrome (PCOS) are being identified in gene expression studies in PCOS tissues; such
pathways may contain key genes in disease etiology. Previous expression studies identified both dickkopf homolog 1 (DKK1)
and DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1) as differentially expressed in PCOS tissue, implicating them as
candidates for PCOS susceptibility. To test this, we genotyped a discovery cohort of 335 PCOS cases and 198 healthy
controls for three DKK1 single nucleotide polymorphisms (SNPs) and four DNAJB1 SNPs and a replication cohort of 396 PCOS
cases and 306 healthy controls for 1 DKK1 SNP and 1 DNAJB1 SNP. SNPs and haplotypes were determined and tested for
association with PCOS and component phenotypes. We found that no single nucleotide polymorphisms were associated
with PCOS risk; however, the major allele of rs1569198 from DKK1 was associated with increased total testosterone
(discovery cohort P = 0.0035) and dehydroepiandrosterone sulfate (replication cohort P = 0.05). Minor allele carriers at
rs3962158 from DNAJB1 had increased fasting insulin (discovery cohort P = 0.003), increased HOMA-IR (discovery cohort
P = 0.006; replication cohort P = 0.036), and increased HOMA-%B (discovery cohort P = 0.004). Carriers of haplotype 2 at
DNAJB1 also had increased fasting insulin, HOMA-IR, and HOMA-%B. These findings suggest that genetic variation in DKK1
and DNAJB1 may have a role in the hyperandrogenic and metabolic dysfunction of PCOS, respectively. Our results also
demonstrate the utility of gene expression data as a source of novel candidate genes in PCOS, a complex and still
incompletely defined disease, for which alternative methods of gene identification are needed.
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Introduction
Familial aggregation and twin studies have established a genetic
etiology for polycystic ovary syndrome (PCOS) [1]. The hallmark of
PCOS is hyperandrogenemia; however, insulin resistance, pancreatic
beta cell dysfunction and chronic inflammation are frequently present
[1,2,3]. Many previous candidate gene studies focused on genes from
androgen synthesis and insulin signaling pathways. Few susceptibility
genes are widely agreed upon, potentially because candidate gene
selection has been based incomplete understanding of the disorder.
Recently a number of expression studies (mRNA and protein) have
been performed in PCOS tissues, including ovary [4], omental fat [5]
and lymphocytes [6]. Remarkably few genes have been reported as
differentially expressed in PCOS tissues in more than one study. One
such gene is dickkopf homolog 1 (DKK1), an inhibitor of the Wnt
signaling pathway and cell growth repressor [4,5]. DKK1 interacts
with the Wnt coreceptor low-density lipoprotein receptor-related
proteins 5 and 6 and influences several functions, including
embryogenesis and cell cycle regulation in cancer pathways [7]. It
has been reported as being under expressed in omental fat [5] and
over expressed in cultured ovarian theca [4] from PCOS subjects.
The second gene we selected for analysis in this study is DnaJ
(Hsp40) homolog, subfamily B, member 1 (DNAJB1), whose
expression was decreased in ovaries from PCOS women [8].
DNAJB1 was also selected as a positional and functional candidate.
It acts in concert with molecular chaperones to regulate protein
folding, protein complex assembly and disassembly, and transport
of proteins across cellular membranes, particularly in the androgen
signaling pathway, and is under transcriptional regulation by
insulin [9]. It is also located within the chromosome 19p13.2
linkage region that has been identified in PCOS susceptibility [10],
implicating DNAJB1 as a potential positional candidate.
Because logical candidates have led to few successes in PCOS
genetics, novel methods of candidate gene selection are needed. In
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the present study we used published expression data to identify
putative molecular targets; selecting two genes, DKK1 and
DNABJ1, from such analysis for association study with PCOS,
conducted in two independent case/control cohorts. A SNP in
DNABJ1 was associated with a measure of insulin resistance in
women with PCOS in both cohorts.
Materials and Methods
Ethics statement
All subjects gave written informed consent; each study was
approved by the Institutional Review Boards of the recruiting
centers and Cedars-Sinai Medical Center.
Subjects and phenotyping
Discovery Cohort. We studied 335 unrelated White PCOS
patients and 198 White control women recruited at two centers, the
University of Alabama at Birmingham (UAB; 287 PCOS and 187
controls) and Cedars-Sinai Medical Center (CSMC; 48 PCOS and
11 controls). Cases were premenopausal, non-pregnant, on no
hormonal therapy, including oral contraceptives, for at least three
months; all PCOS subjects met 1990 NIH criteria [11]. Parameters
for defining hirsutism, hyperandrogenemia, ovulatory dysfunction,
and exclusion of related disorders were previously reported [12].
Controls were healthy women, with regular menstrual cycles and no
evidence of hirsutism, acne, alopecia, or endocrine dysfunction and
had not taken hormonal therapy (including oral contraceptives) for
at least three months. Controls were recruited by word of mouth
and advertisements calling for ‘‘healthy women.’’
Replication Cohort. We assembled a cohort of 396 unrelated
White PCOS patients and 306 White control women. The replication
cohort was constituted from three sources: 380 PCOS subjects (all
meeting 1990 NIH criteria) and 71 healthy controls previously
recruited by R. S. Legro [13], 16 PCOS subjects and 2 healthy controls
recruited at Cedars-Sinai Medical Center using the same criteria as
those used in the discovery cohort; and 233 white control women
derived from the Cholesterol and Atherosclerosis Pharmacogenetics
(CAP) study, a component of the Pharmacogenomics and Risk of
Cardiovascular Disease (PARC) Study [14].
Subjects recruited at UAB and CSMC were evaluated per a
previously described protocol [12]. Fasting glucose and insulin
were also obtained in a subset (70%) of the cases (non-diabetic).
The subset of subjects with fasting glucose and insulin did not
differ demographically or hormonally from the study subjects
overall. The computer-based homeostasis model assessment
(HOMA, www.dtu.ox.ac.uk/homa) was used to calculate indices
of insulin resistance (HOMA-IR) and insulin secretion (i.e. percent
beta-cell function or HOMA-%B) utilizing the fasting glucose and
insulin levels. This computer model was also applied to generate
HOMA data in the replication cohort, on whom fasting insulin
and glucose were measured in .90% of subjects. Table 1 presents
clinical characteristics of both cohorts.
Genotyping and haplotype determination
Discovery genotyping was performed on three DKK1 single
nucleotide polymorphisms (SNPs) (rs2241529, rs1569198,
rs2288335) and four DNAJB1 SNPs (rs7003, rs1803768, rs4926222,
rs3962158) selected using genotype data of the CEU (Utah residents
with ancestry from northern and western Europe) population of the
HapMap database (release 24, http://hapmap.ncbi.nlm.nih.gov/).
These SNPs were selected because they are predicted to tag SNPs
across the entirety of each gene, plus 10 kb upstream and 10 kb
downstream. These SNPs capture 21 of 26 (81%) of the CEU
HapMap SNPs at r2.0.8 for the two genes. Replication genotyping
was performed on two of the discovery SNPs; rs1569198 from DKK1
and rs3962158 from DNAJB1. All genotyping was performed using
Applied Biosystems Taqman Assays-on-Demand (Applied Biosys-
tems, Foster City, CA) according to manufacturer’s instructions.
Haploview (version 4.1) was used to calculate linkage disequi-
librium (LD, the D’ statistic) between each pair of SNPs and
determine haplotypes and their frequencies [15]. The solid spine
of LD algorithm in Haploview was used to determine haplotype
blocks. Only subjects whose haplotype assignment was .95%
certain were analyzed.
Statistical analysis
Unpaired t-tests and chi-square tests were used to compare
clinical characteristics between cases and controls; quantitative traits
were log- or square-root-transformed as appropriate to reduce non-
normality. Data are presented as median (interquartile range).
Genotypic association with PCOS status was evaluated using
logistic regression, adjusting for recruitment site, BMI and age.
Association between genotype and quantitative traits (conducted
separately in cases and controls) was performed using linear
regression adjusting for site, age and BMI in all analyses except
those in which BMI was the dependent variable, wherein analyses
were adjusted for site and age. To handle multiple testing in the
discovery cohort significance was taken as P,0.008, considering
that we analyzed two LD groups of SNPs (one per gene) against
three families of traits (PCOS diagnosis, androgens and metabolic
traits), yielding a Bonferroni correction factor of 6 (i.e. six
independent comparisons). In the replication cohort, significance
was taken as P,0.05, because the goal was to confirm the
associations made in the discovery cohort. To limit multiple testing
in the replication cohort, we only examined SNPs that displayed
associations in the discovery cohort.
Results
Discovery cohort
We genotyped three SNPs from DKK1 and four SNPs from
DNAJB1 in the discovery cohort (Table 2), where the overall
Table 1. Clinical Characteristics of PCOS and control subjects.
Discovery Replication
Control
(n= 198)
PCOS
(n=335)
Control
(n = 306)
PCOS
(n=396)
Age (yr) 32.5 (17.0) 27.0 (11.1)* 51.0 (23.7) 28.0 (9.0)*
BMI (kg/m2) 24.7 (5.9) 33.4 (14.7)* 25.9 (8.3) 34.9 (12.3)*
Total testosterone
(nmol/l)
1.40 (0.94) 2.63 (1.14)* 1.0 (0.52) 2.43 (1.11)*
DHEAS (mmol/l) 2.58 (2.04) 5.68 (4.57)* 3.70 (1.75) 5.72 (3.94)*
Insulin (pmol/l) 41.4 (39.0) 96.0 (108.0)* 72.0 (45.0) 126.0 (96.0)*
Glucose (mmol/l) 4.77 (0.56) 4.77 (0.72) 5.01 (0.68) 4.86 (0.64)
HOMA-IR 0.95 (0.84) 2.01 (2.13)* 1.58 (0.96) 2.69 (1.83)*
HOMA-%B 104.1 (57.0) 166.9 (108.8)* 129.5 (58.3) 196.6 (81.0)*
*P,0.001 compared to control group. Data are median (interquartile range). In
the replication cohort, androgen measurements were available only in the cases
and controls recruited by R. S. Legro.
Abbreviations: BMI: body mass index; mFG: modified Ferriman-Gallwey
hirsutism score; NA: Data not Available; HOMA-IR, homeostasis model
assessment of insulin resistance; HOMA-%B, homeostasis model assessment of
beta-cell function (insulin secretion).
doi:10.1371/journal.pone.0020120.t001
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genotyping success rate was 95.4% (ranging from 95.1–97.0% for
individual SNPs). LD among markers (D’) in DKK1 ranged from
0.93 to 1.0 (average pairwise D’ of 0.96), while LD in DNAJB1
ranged from 0.03 to 1.0 (average pairwise D’ of 0.54). Haploview
generated a single haplotype block including all three markers in
DKK1 and a single block encompassing all four markers in
DNAJB1 (Figure 1).
SNPs in DKK1 and DNAJB1 were not associated with PCOS
status. In women with PCOS, one SNP in DKK1 (rs1569198) was
associated with total testosterone, with major A allele carriers
having increased testosterone levels (AA/AG: 2.74 (1.21) vs. GG:
2.36 (0.90) nmol/l; P = 0.0035). PCOS women carriers of the
minor T allele at rs3962158 (Asp4Asp) in exon 1 of DNAJB1 had
increased insulin (CC: 78.0 (92.4) vs. CT/TT: 108.0 (124.5) pmol/l;
P = 0.0031); increased HOMA-IR (CC: 1.72 (1.96) vs. CT/TT:
2.34 (2.39); P = 0.006) and increased HOMA-%B (CC: 145.2 (99.2)
vs. CT/TT: 177.2 (108.6); P = 0.004). These SNP associations
were not observed in the control women. No associations with
BMI were observed.
Three common haplotypes (frequency .5%) were identified for
the DKK1 gene region (Table 2). No DKK1 haplotype was
associated with PCOS status or quantitative traits at our selected
level of significance (P,0.008). Four common haplotypes were
identified for DNAJB1 (Table 2). PCOS women carriers of
haplotype 2 had increased insulin (non-carriers: 78.0 (92.4) vs.
carriers: 108.0 (120.9) pmol/l; P = 0.006), HOMA-IR (non-
carriers: 1.76 (1.90) vs. carriers: 2.33 (2.43); P = 0.003) and
HOMA-%B (non-carriers: 146.3 (97.7) vs. carriers: 176.6 (113.7);
P = 0.002). This haplotype carries the minor allele of rs3962158,
which was also associated with each of these traits in the single
marker analysis. These haplotype associations were not observed
in the control women.
Replication cohort
We selected the two significant SNPs from the discovery phase
of the study for replication. The genotyping success rate for
rs1569198 was 95.7% and for rs3962158 was 97.3%, with 100%
concordance observed in duplicate samples run both within the
replication study samples, and across the replication and discovery
study samples. The minor allele frequencies of rs1569198 (PCOS
0.48, control 0.51, overall 0.49) and rs3962158 (PCOS 0.31,
control 0.30, overall 0.31) were the same as the frequencies
observed in the discovery cohort. We observed association
(additive model) between DKK1 SNP rs1569198 and dehydroepi-
androsterone sulfate (DHEAS), with increasing copies of the A
allele correlating with increasing DHEAS (AA: 2229.0 (1551.3),
AG: 2099.0 (1373.8), GG: 1978.0 (1520.0) nmol/l; P = 0.05). We
did not replicate the association between total testosterone and
rs1569198. We did, however, replicate the significant association
between carriers of the minor T allele at rs3962158 of DNAJB1
with increased HOMA-IR under the same dominant model (CC:
2.57 (1.65) vs. CT/TT: 2.77 (1.98); P = 0.036).
Discussion
In an attempt to circumnavigate arbitrary bias introduced in the
selection of candidate genes for PCOS, we evaluated mRNA and
protein expression data reported from several PCOS tissues in
order to identify novel susceptibility genes, DKK1 and DNAJB1.
These results suggest that variation in gene expression may be an
important factor in identifying relevant PCOS pathways. This
strategy was employed to select the 17b-hydroxysteroid dehydro-
genase type 6 (HSD17B6) gene, which exhibited increased activity
in PCOS ovaries, as a candidate gene for PCOS [16]; we and
others ultimately replicated association of variants in this gene with
metabolic phenotypes of PCOS [17,18]. Others have performed
network analysis on PCOS microarray data to identify pathways
that may be most relevant to the development of the disorder [19].
A DKK1 variant, rs1569198, was associated with testosterone
levels in PCOS subjects in our discovery cohort, with carriers of
the major allele having an elevated testosterone level. This result is
consistent with the observation that a murine homolog of DKK1
plays a role in testicular testosterone production [20]. DKK1 is
expressed in a number of tissues including ovary, testis and adipose
tissue, with increased expression in PCOS ovarian theca [4]. DKK1
has been identified as one of the most upregulated genes in
testosterone responsive tissues, such as the dermal papilla [21],
suggesting its expression may be regulated by androgens. In a
recent report designed to identify proteins that act in androgen-
dependent hair loss, DKK1 was reported as a dihydrotestosterone-
inducible transcript, and also caused apoptosis in follicular
keratinocytes [21]. These data suggest a role for DKK1 in the
regulation of cell cycle in androgen responsive tissues, and further
studies in ovary, particularly ovarian theca may confirm this. In a
study of genetic determinants of bone phenotypes in men,
rs1569198 was associated with hip axis length [22], which indicate
potential roles for DKK1 and this SNP in particular in a number of
pathways, including those under hormonal regulation.
That we did not replicate the association of rs1569198 with
testosterone deserves comment. The replication of associations
such as these presents several challenges; the most important is the
accumulation of an appropriate replication cohort, which must
consist of an equal or large sample size of ethnically matched
Table 2. SNP and haplotype information for the DKK1 and
DNAJB1 gene regions in the discovery cohort.
Variant Location Alleles
PCOS
MAF
Control
MAF
Overall
MAF
SNPs
DKK1
rs2241529 Exon 2 (Ala106Ala) G/A 0.41 0.46 0.43
rs1569198 Intron 3 A/G 0.49 0.47 0.48
rs2288335 39 region G/A 0.08 0.09 0.08
DNAJB1
rs7003 39 UTR G/A 0.12 0.15 0.13
rs1803768 39 UTR G/A 0.04 0.06 0.05
rs4926222 Intron 2 G/A 0.16 0.15 0.16
rs3962158 Exon 1 (Asp4Asp) G/A 0.31 0.28 0.30
Haplotypes
DKK1
1 G-G-G 0.48 0.45 0.47
2 A-A-G 0.41 0.43 0.41
3 G-A-A 0.08 0.08 0.08
DNAJB1
1 G-G-G-G 0.41 0.42 0.41
2 G-G-G-A 0.31 0.28 0.3
3 G-G-A-G 0.16 0.16 0.16
4 A-A-G-G 0.08 0.09 0.08
The order of SNPs in the haplotypes corresponds to the order of SNPs in the
table. MAF = minor allele frequency.
doi:10.1371/journal.pone.0020120.t002
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subjects, with similar disease phenotype and quantitative trait
measures. The appropriateness of our replication cohort is
substantiated by our replication of the association between
rs3962158 and HOMA-IR. The replication of genetic association
with testosterone poses a particular challenge, given the difficulty
in precisely measuring this trait, particularly in women [23,24]. In
the replication cohort, we identified a nominal association of the
major allele of rs1569198 with increased DHEAS, representing
either a coincidence or supporting a role in androgen production
or clearance. If the SNP does affect both testosterone and DHEAS
levels, the lack of observation of association with both traits in both
cohorts may be related to statistical chance or imprecision of
androgen measurement in women.
Of particular interest as a candidate identified via differential
expression was DNAJB1 as it lies in the previously identified PCOS
linkage region (microsatellite marker D19S884) on chromosome
19p13.2 [10] and acts as a molecular chaperone. Androgen receptor
function (including ligand binding and nuclear translocation) depends
on its interaction with heat shock proteins and their co-chaperones
[25]. DNAJB1 acts as a co-chaperone in a number of pathways
including androgen receptor and glucocorticoid receptor signaling. An
androgenic protein co-chaperone, DNAJB1 is under transcriptional
regulation by insulin, with increased hepatic expression demonstrated
under conditions of reduced insulin [9].DNAJB1may thus represent a
common factor at the nexus of both the androgenic and insulin
pathways that are frequently dysfunctional in PCOS.
The functional role of the associated DKK1 and DNAJB1 SNPs
is unknown. The DKK1 SNP rs1569198 is an intronic SNP, and
the DNAJB1 SNP rs3962158 does not change the amino acid at
position 4. These SNPs, purposefully selected as tagging SNPs,
may not be causal, but may be in LD with functional variants
elsewhere in their genes or in the promoters. In particular,
HapMap data indicate that the DKK1 SNP is in LD with several
SNPs in the promoter region of the gene. Tissue specific gene
expression studies in genotyped subjects should be undertaken to
further elucidate the role of variation in these genes on gene
expression.
Despite many candidate gene studies in PCOS, few biologically
selected candidates have been replicated. The use of expression
data from PCOS subjects may result in the identification of novel
susceptibility loci. In the present study, we used published
expression data to select two putative candidate genes for analysis,
DKK1 and DNAJB1. By using a discovery and replication
approach we have identified and replicated DNAJB1 as a potential
gene important in the insulin resistance of PCOS. While not
associated with PCOS itself, genetic variation in DNAJB1 and
perhaps DKK1 may act as modifiers, affecting the metabolic and
androgenic pathways of PCOS, respectively. In conclusion, gene
expression data appears to be a useful source of candidate genes in
complex and poorly understood diseases such as PCOS.
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Figure 1. Gene structure and linkage disequilibrium plot for DKK1 and DNAJB1. The gene structure is shown at top, with exons shown as
filled boxes, untranslated regions as unfilled boxes and introns as connecting lines. The locations of the genotyped SNPs relative to the exons are
indicated. The linkage disequilibrium (LD) plot at the bottom displays D’ values (%) for each pair of SNPs in the box at the intersection of the
diagonals from each SNP. The solid blocks indicate D’ = 1 for the corresponding pair of variants. The darker solid blocks indicate a logarithm of the
odds (LOD) score $2 for the corresponding pair of variants; lighter solid blocks indicate a LOD score ,2. Within each gene, SNPs were considered
together in one haplotype block as indicated.
doi:10.1371/journal.pone.0020120.g001
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